Welcome to our dedicated page for MOLECULAR PARTNERS news (Ticker: MOLN), a resource for investors and traders seeking the latest updates and insights on MOLECULAR PARTNERS stock.
Molecular Partners AG develops DARPin therapeutics, a class of custom-built protein drugs used in oncology-focused drug development. Company updates center on its clinical-stage and preclinical pipeline, including Radio-DARPin candidates for targeted radiopharmaceuticals, tumor-localized immune activation programs, and next-generation immune cell engagers for cancer.
Recurring developments include scientific conference presentations, peer-reviewed clinical data, preclinical research, partnership activity, annual financial results, and shareholder-meeting governance. Key program references include MP0712, a DLL3-targeting Radio-DARPin for small cell lung cancer and other DLL3-expressing neuroendocrine cancers; MP0317, a FAPxCD40 DARPin designed for tumor-localized CD40 activation; and Switch-DARPin and T cell engager candidates for solid tumors and hematologic cancers.
Molecular Partners (SIX: MOLN; NASDAQ: MOLN) signed a non-exclusive development agreement with Eckert & Ziegler to advance its Radio-DARPin pipeline using alpha and beta emitters.
The collaboration covers development and manufacturing support for Actinium-225 (225Ac) and Lutetium-177 (177Lu), leveraging Eckert & Ziegler’s Alpha Laboratory in Berlin. The company plans to present pre-clinical multi-isotope data at a March 2026 summit and notes its lead candidate MP0712 recently opened a Phase 1/2a trial in small cell lung cancer.
Molecular Partners (NYSE: MOLN) presented first-in-human imaging and dosimetry data for DLL3-targeting Radio-DARPin MP0712 at TWC 2026. Data from five evaluable patients using diagnostic 203Pb show tumor-specific uptake, favorable biodistribution, and dosimetry supporting a U.S. Phase 1/2a study of therapeutic 212Pb. The Phase 1/2a study is open in the U.S. with initial clinical data expected in 2026. A company webcast and conference call were held Feb 2, 2026, with commentary from Prof. Ken Herrmann.
Molecular Partners (NASDAQ:MOLN) provided a clinical update ahead of J.P. Morgan, reporting a cleared IND and the start of a Phase 1/2a trial for radio-DARPin MP0712 (DLL3) with first patient dosing expected in Q1 2026 and initial data anticipated in 2026. The company reported CHF 93.1 million cash as of Dec 31, 2025, sufficient to fund operations into 2028. Additional highlights: compassionate-program 203Pb imaging for MP0712 to be presented at TWC 2026; Phase 2 investigator-initiated trial of MP0317 in cholangiocarcinoma open (target 75 patients); ongoing Phase 1/2a for MP0533 with an update planned in H1 2026.
Molecular Partners (SIX/NASDAQ: MOLN) will present corporate and clinical updates at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. CEO Patrick Amstutz will speak on Thursday, January 15, 2026 at 10:30–11:10 AM PT (19:30–20:10 CET) at the Westin St. Francis.
A live webcast of the presentation will be available via the company website under the Events tab. The presentation will cover the company’s latest developments and 2025 outlook.
Molecular Partners (SIX/NASDAQ: MOLN) formed a Scientific Advisory Board (SAB) for its radiopharmaceutical program, chaired by Prof. Ken Herrmann, M.D., to guide transition from early clinical validation to strategic development decisions.
The SAB includes James Cook, Jason Lewis, Ph.D., and Michael Morris, M.D., and will advise on candidate development, platform expansion (additional isotopes and targeting), and clinical strategy. The company's lead Radio-DARPin MP0712 is a 212Pb-based DLL3-targeting candidate (co-developed with Orano Med) with first human images presented recently and plans for phase 1 initiation. A second program, MP0726, targets mesothelin for cancers including ovarian cancer. The release emphasizes Radio-DARPins as vectors to deliver alpha-emitting isotopes selectively to tumors.
Molecular Partners (NASDAQ: MOLN) presented updated Phase 1/2a data for tetra-specific T-cell engager MP0533 in relapsed/refractory AML at ASH on December 7, 2025. As of the September 1, 2025 cut-off, 54 patients received MP0533 and 8 of 48 evaluable patients responded (5 composite complete responses and 3 MLFS). Densified and higher-frequency dosing (cohorts 8–9) was tolerable, increased serum exposure in cycle 1, and showed preliminary antitumor activity. Responses clustered in patients with 20% bone marrow blasts at baseline. Cohort 10 is ongoing with data expected in 2026.
Molecular Partners (NASDAQ: MOLN) presented new human imaging and mechanism data for MP0712, a DLL3-targeting Radio-DARPin, at TRP Summit Europe on Nov 12, 2025. A named‑patient case from South Africa showed specific tumor uptake at 24 hours and sustained signal over 4 days using 203Pb imaging, with limited kidney and liver exposure. The company filed a Phase 1 IND for MP0712 and expects to initiate the US trial by end‑2025, with initial clinical data anticipated in 2026. Presentation and webcast details were provided for Nov 12, 2025.
Molecular Partners (NASDAQ: MOLN) will present additional preclinical proof-of-concept data on its logic-gated CD3 Switch-DARPin T cell engager with CD2 co-stimulation at SITC 2025 (Nov 5-9; poster Nov 7).
Preclinical results show the AND-gated Switch-DARPin selectively triggered T cell cytotoxicity only against cells co-expressing MSLN and EpCAM, improved T cell activation and proliferation with CD2/CD3 co-stimulation, and induced significant tumor regression in a xenograft model without systemic cytokine release, indicating a favorable safety signal.
Molecular Partners (NASDAQ: MOLN) will present updated Phase 1/2a data for MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), at the ASH Annual Meeting on December 7, 2025.
The poster summarizes first-in-human, multicenter, open-label results in relapsed/refractory AML and MDS/AML (ClinicalTrials.gov: NCT05673057). MP0533 showed an acceptable safety profile across dose ranges 1–9; densified dosing used in DR 8–9 appears tolerable and preliminary antitumor activity is described. The study is dosing in DR 10. Abstracts posted on the ASH website from 9:00 AM ET on November 3, 2025.
Molecular Partners (NASDAQ:MOLN / SIX:MOLN) filed an IND for MP0712 (212Pb DLL3 Radio-DARPin) with a Phase 1 start expected before year-end 2025 and first compassionate-care 203Pb images to be shown at the TRP Summit in November. Updated MP0533 Phase 1/2a data (AML) will be presented at ASH in December, with cohort 8 showing 3 of 8 evaluable responders and one patient >12 months on treatment.
Protocol approved for a Phase 2 investigator-initiated trial of MP0317 (FAP x CD40). Cash, equivalents and short-term deposits were CHF 105 million as of Sept 30, 2025, and the company expects runway until 2028. Full‑year 2025 operating expense guidance: CHF 55–60 million.